Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMRA NASDAQ:ERAS NASDAQ:ORKA NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$26.01+7.4%$23.72$2.45▼$38.33$1.49B1.46862,920 shs569,219 shsERASErasca$18.32+0.2%$13.64$1.24▼$24.28$5.69B0.735.93 million shs5.41 million shsORKAOruka Therapeutics$95.17+2.9%$67.98$10.97▼$97.78$5.58B-0.261.58 million shs1.75 million shsXENEXenon Pharmaceuticals$60.36+0.4%$54.77$30.00▼$63.95$5.81B0.621.72 million shs1.25 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock+7.43%+13.38%+4.54%+3.71%+662.76%ERASErasca+0.16%+21.57%+42.68%+10.36%+1,342.52%ORKAOruka Therapeutics+2.90%+14.11%+62.60%+88.72%+748.97%XENEXenon Pharmaceuticals+0.38%+10.53%+10.29%+6.47%+92.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$26.01+7.4%$23.72$2.45▼$38.33$1.49B1.46862,920 shs569,219 shsERASErasca$18.32+0.2%$13.64$1.24▼$24.28$5.69B0.735.93 million shs5.41 million shsORKAOruka Therapeutics$95.17+2.9%$67.98$10.97▼$97.78$5.58B-0.261.58 million shs1.75 million shsXENEXenon Pharmaceuticals$60.36+0.4%$54.77$30.00▼$63.95$5.81B0.621.72 million shs1.25 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock+7.43%+13.38%+4.54%+3.71%+662.76%ERASErasca+0.16%+21.57%+42.68%+10.36%+1,342.52%ORKAOruka Therapeutics+2.90%+14.11%+62.60%+88.72%+748.97%XENEXenon Pharmaceuticals+0.38%+10.53%+10.29%+6.47%+92.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMRADamora Therapeutics, Inc. Common Stock 2.91Moderate Buy$42.4363.12% UpsideERASErasca 2.60Moderate Buy$20.119.78% UpsideORKAOruka Therapeutics 2.82Moderate Buy$131.3037.96% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.2027.90% UpsideCurrent Analyst Ratings BreakdownLatest DMRA, XENE, ERAS, and ORKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$120.006/18/2026DMRADamora Therapeutics, Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/12/2026DMRADamora Therapeutics, Inc. Common Stock WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$35.006/11/2026ERASErasca Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/11/2026DMRADamora Therapeutics, Inc. Common Stock HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/8/2026DMRADamora Therapeutics, Inc. Common Stock TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/4/2026ERASErasca Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.006/4/2026ERASErasca Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$9.00 ➝ $16.006/3/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026ORKAOruka Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$180.005/28/2026DMRADamora Therapeutics, Inc. Common Stock WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$35.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/A($110.11) per shareN/AERASErascaN/AN/AN/AN/A$1.05 per shareN/AORKAOruka TherapeuticsN/AN/AN/AN/A$9.69 per shareN/AXENEXenon Pharmaceuticals$7.50M778.00N/AN/A$7.53 per share8.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMRADamora Therapeutics, Inc. Common Stock-$209.84M-$5.58N/AN/AN/AN/A-428.30%-114.62%8/5/2026 (Estimated)ERASErasca-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%8/11/2026 (Estimated)ORKAOruka Therapeutics-$105.43M-$1.94N/AN/AN/AN/A-26.16%-25.00%8/10/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%8/10/2026 (Estimated)Latest DMRA, XENE, ERAS, and ORKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026DMRADamora Therapeutics, Inc. Common Stock-$0.3878-$0.62-$0.2322-$0.62N/AN/A5/13/2026Q1 2026ORKAOruka Therapeutics-$0.52-$0.48+$0.04-$0.48N/AN/A5/11/2026Q1 2026ERASErasca-$0.1150-$0.60-$0.4850-$0.60N/AN/A5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMRADamora Therapeutics, Inc. Common StockN/A22.4922.48ERASErascaN/A9.529.52ORKAOruka TherapeuticsN/A23.7623.76XENEXenon PharmaceuticalsN/A27.7927.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMRADamora Therapeutics, Inc. Common Stock14.20%ERASErasca67.78%ORKAOruka Therapeutics56.44%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipDMRADamora Therapeutics, Inc. Common Stock0.40%ERASErasca14.20%ORKAOruka Therapeutics23.49%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMRADamora Therapeutics, Inc. Common Stock4061.55 million61.31 millionNo DataERASErasca120310.98 million266.83 millionOptionableORKAOruka TherapeuticsN/A60.31 million46.15 millionN/AXENEXenon Pharmaceuticals21096.67 million92.73 millionOptionableDMRA, XENE, ERAS, and ORKA HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by AnalystsJune 25, 2026 | americanbankingnews.comXenon Pharmaceuticals Stock Gains 22% in Six Months: Here's WhyJune 23, 2026 | zacks.comCommodore Capital LP Sells 900,000 Shares of Xenon Pharmaceuticals Inc. $XENEJune 18, 2026 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Polar Capital Holdings PlcJune 17, 2026 | marketbeat.comAvoro Capital Advisors LLC Acquires 24,444 Shares of Xenon Pharmaceuticals Inc. $XENEJune 17, 2026 | marketbeat.comSofinnova Investments Inc. Takes $2.69 Million Position in Xenon Pharmaceuticals Inc. $XENEJune 16, 2026 | marketbeat.comNEXTBio Capital Management LP Takes Position in Xenon Pharmaceuticals Inc. $XENEJune 14, 2026 | marketbeat.comRhenman & Partners Asset Management AB Boosts Holdings in Xenon Pharmaceuticals Inc. $XENEJune 13, 2026 | marketbeat.comAssessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation EstimateJune 12, 2026 | finance.yahoo.comGillian Cannon Sells 1,190 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) StockJune 9, 2026 | insidertrades.comFiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENEJune 9, 2026 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Purchased by Westfield Capital Management Co. LPJune 6, 2026 | marketbeat.comXenon Pharmaceuticals Inc. Rings the Opening BellJune 2, 2026 | nasdaq.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | globenewswire.comJPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)May 24, 2026 | finance.yahoo.comWhat to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA FilingMay 19, 2026 | finance.yahoo.comXenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comA Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash RunwayMay 11, 2026 | finance.yahoo.comDid Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?May 11, 2026 | finance.yahoo.comXenon Highlights Positive Phase 3 Azetukalner Seizure DataMay 8, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMRA, XENE, ERAS, and ORKA Company DescriptionsDamora Therapeutics, Inc. Common Stock NASDAQ:DMRA$26.01 +1.80 (+7.43%) As of 06/30/2026 04:00 PM EasternGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Erasca NASDAQ:ERAS$18.32 +0.03 (+0.16%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$18.14 -0.18 (-0.96%) As of 06/30/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Oruka Therapeutics NASDAQ:ORKA$95.17 +2.68 (+2.90%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$96.87 +1.70 (+1.79%) As of 06/30/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Xenon Pharmaceuticals NASDAQ:XENE$60.36 +0.23 (+0.38%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$61.04 +0.69 (+1.13%) As of 06/30/2026 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
